ClinicalTrials.gg
RecruitingNCT07713485Updated Nov 12, 2026

Study of XmAb412 in Healthy Participants

A Phase 1 interventional study of XmAb412 Monoclonal Bispecific Antibody and Placebo in Not Applicable - Healthy Adult Participants, sponsored by Xencor, Inc.. Recruiting at 2 sites in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Xencor, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Inflammatory Bowel Diseases with a site in Australia — 11 open to participants now, 13 under way, 3 of them phase 3. Inflammatory Bowel Diseases · Australia.

Planned enrollment
26th of 49
128 · median 139
Started
2026
with 3 others
Phase 1
7 of 54
2 open now
Primary completion
2027-08
later than 6 of 12 live
Registered
53rd of 54
by date

Among the 54 studies in Inflammatory Bowel Diseases with a site in Australia, this one is the 26th largest by planned enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2026, is one of 7 in phase 1, reaches primary completion later than 6 of the 12 other live ones, and was the 53rd registered.

Inflammatory Bowel Diseases

1,552 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

11 of the 54 studies in Inflammatory Bowel Diseases with a site in Australia are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 275 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 115 (42%) stop at 75 or younger; 76 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Inflammatory Bowel Diseases with a site in Australia, or all of them as a file.
02

Study summary

This Phase 1 Study will evaluate the safety, tolerability, pharmacokinectics and pharmacodynamics of XmAb412 in healthy adult participants

Read the detailed description

This study consists of 2 parts, as follows:

In Part A, participants will receive a single dose of XmAb412 using subcutaneous (SC) or intravenous (IV) administration route.

In Part B, participants will receive multiple doses of XmAb412 or placebo using SC or IV administration route.

03

Conditions studied

  • Not Applicable - Healthy Adult Participants

Keywords

  • Inflammatory Bowel Disease
  • Health Adult Participants
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-55 years old
  • Must be in good health with no significant medical history
  • 18-35 kg/m2
  • use consistent with local regulations
  • Able and willing to provide written

Exclusion criteria

Exclusion Criteria:

  • Any physical condition that prohibits study completion
  • Known to the trial intervention or any of its components
  • , and positive
  • abnormal
  • Use of other products within 5 half lives from Screening
  • Blood or plasma donation within 60 days from Screening
  • Pregnant or breastfeeding

Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
128 participants (estimated)

Study arms

  • Active comparator
    Part A: Active Drug

    Active XmAb412 to be administered to healthy adult participants.

    Drug: XmAb412 Monoclonal Bispecific Antibody

  • Placebo comparator
    Part A: Placebo

    Placebo Comparator to be administered to healthy participants.

    Drug: Placebo

  • Active comparator
    Part B: Active

    Active XmAb412 to be administered to healthy participants.

    Drug: XmAb412 Monoclonal Bispecific Antibody

  • Placebo comparator
    Part B: Placebo

    Placebo Comparator to be administered to healthy participants.

    Drug: Placebo

Interventions

  • DrugXmAb412 Monoclonal Bispecific Antibody

    Monoclonal Bispecific Antibody

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of XmAb412 in healthy adult participants (Part A and Part B)

    Time frame: Up to 28 weeks

Secondary outcomes

  1. Serum PK parameters of XmAb412 in healthy adult participants (Part A and Part B)

    Time frame: Up to 28 weeks

  2. Cmax (Maximum concentration of drug)

    Time frame: Up to 28 weeks

  3. Tmax (Time of maximum concentration of drug)

    Time frame: Up to 28 weeks

  4. • AUC0-last (Area under the curve drug concentration-time curve to last concentration)

    Time frame: Up to 28 weeks

  5. • Repeat dose cohorts: AUC0-tau (AUC within a dosing interval

    Time frame: Up to 28 weeks

  6. • AUC0-inf (AUC from time 0 extrapolated to infinity

    Time frame: Up to 28 weeks

  7. • t1/2 (terminal elimination half-life

    Time frame: Up to 28 weeks

  8. • CL/F (apparent) total body clearance

    Time frame: Up to 28 weeks

  9. • Vz/F (apparent volume of distribution

    Time frame: Up to 28 weeks

07

Study locations

2 of 2 sites recruiting
  • Xencor Investigative Site
    Joondalup, Western Australia 6027, Australia
    Recruiting
  • Xencor Investigative Site
    Nedlands, Western Australia 6009, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Aug 2027, 13 months after the start.

Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's planned 13 months is above that.

Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion May 2027 → Aug 2027 and completion Mar 2028 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 20, 2026
StartActual
Jul 13, 2026
Primary completionEst.
Aug 2027was May 2027
CompletionEst.
Aug 2027was Mar 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 2027→Aug 2027
Nov 12, 2026
Study completion
Mar 2028→Aug 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion May 2027→Aug 2027
    Study completion Mar 2028→Aug 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07713485
Lead sponsor
Xencor, Inc.
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
Jul 13, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

412 Study Information
Contact
XmAb412-01info@xencor.com
412 Study Information
study director · Xencor, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion